Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07516561
PHASE3

Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia.

Sponsor: Apsen Farmaceutica S.A.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and safety of APSMNF in the treatment of male androgenetic alopecia.

Official title: Phase III Randomized, Multicenter, Double-blind, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia.

Key Details

Gender

MALE

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

336

Start Date

2026-07-07

Completion Date

2029-08-02

Last Updated

2026-04-08

Healthy Volunteers

No

Interventions

DRUG

APSMNF 1

Administer twice a day during 24 weeks.

DRUG

APSMNF 2

Administer twice a day during 24 weeks.

DRUG

Eniagor®

Administer twice a day during 24 weeks.

Locations (1)

Clinica Geral Investiga Ltda

Campinas, São Paulo, Brazil